精華製藥(002349.SZ):終止研發VEGFR-2單抗及PDL-1單抗產品
格隆匯2月19日丨精華製藥(002349.SZ)公佈,公司於2015年10月29日與美國Kadmon Corporation, LLC簽署《合作與授權協議》,就VEGFR-2全人源單克隆抗體和PDL-1全人源單克隆抗體產品開發進行合作。
截至目前,上述兩項產品仍處於臨牀前研發階段,研究結果及進度不符合立項預期。考慮到市場競爭實際情況,預計本項目受益不明顯且面臨較大風險,經與美國kadmon公司協商,決定終止項目的研發工作。
公司擬將上述全人源單克隆抗體產品研發項目已確認的直接支出1276.73萬元及支付的專利許可費2524.95萬元,全部計入2019年度研發費用,扣除所得税影響後預計減少公司2019年度淨利潤約2946.30萬元,具體金額將以會計師確認為準。
公司表示,新藥研發屬於高投入、高風險項目,研發風險不可避免,公司正對研發項目結構進行調整,更加聚焦中成藥和經典化學藥的研發、現有品種的二次開發,提升公司的核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.